ReviewAmerican journal of Alzheimer's disease and other dementias2018
Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease.
Review in American journal of Alzheimer's disease and other dementias, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- The Cholinergic Drug Galantamine Alleviates Oxidative Stress Alongside Anti-inflammatory and Cardio-Metabolic Effects in Subjects With the Metabolic Syndrome in a Randomized Trial.Frontiers in immunology · 2021Trial
- Isolation, modification, structure-activity relationship (SAR) and molecular docking studies of isoflavones from Derris scandens as potent dual AChE/BuChE inhibitors.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Neuromodulation to Promote Recovery Following Traumatic Brain Injury: A Narrative Review of Current Pharmacologic and Non-Pharmacologic Approaches.Brain sciences · 2026Review
- Protective effects of alkaloidal fraction of Elaeocarpus angustifolius Blume against AlCl₃-evoked neurotoxicity: insights from an in vivo model of Alzheimer's disease.Metabolic brain disease · 2025Article
- Hippocampal Interneurons Shape Spatial Coding Alterations in Neurological Disorders.Molecular neurobiology · 2025Review
- Design, Synthesis, and Computational Studies of NovelACS omega · 2025Article
- Medical Comorbidities in Alzheimer's Disease: An Autopsy Confirmed Study with a Focus on Sex-Differences?Clinical neuropsychiatry · 2025Article
- Assessment of Anti-Alzheimer Pursuit of Jambolan Fruit Extract and/or Choline against AlClToxics · 2023Article
- Microorganism-Derived Molecules as Enzyme Inhibitors to Target Alzheimer's Diseases Pathways.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The role of the gut microbiota and fecal microbiota transplantation in neuroimmune diseases.Frontiers in neurology · 2023Review
- Donepezil Beyond Alzheimer's Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases.Iranian journal of pharmaceutical research : IJPR · 2022Review
- Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer's Disease. Review of Reviews.Biomedicines · 2021Review
- Melanin: Production from Cheese Bacteria, Chemical Characterization, and Biological Activities.International journal of environmental research and public health · 2021Article
- Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer's disease.Current medical research and opinion · 2021Article
- Deep Brain Stimulation for Alzheimer's Disease: Stimulation Parameters and Potential Mechanisms of Action.Frontiers in aging neuroscience · 2021Review
- Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice.The journal of physiological sciences : JPS · 2019Article
- Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus.Therapeutic advances in chronic disease · 2019Review
- Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease.Cardiology research and practice · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elderly patients with Alzheimer's disease (AD) and other dementias are at high risk of polypharmacy and excessive polypharmacy for common coexisting medical conditions. Polypharmacy increases the risk of drug-drug and drug-disease interactions in these patients who may not be able to communicate early symptoms of adverse drug events. Three acetylcholinesterase inhibitors (ACHEIs) have been approved for AD: donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne). They are also used off-label for other causes of dementia such as Lewy body and vascular dementia. We here report evidence from the literature that ACHEI treatment, prescribed for cognitive impairment, can reduce the load of medications in patients with AD by also addressing cardiovascular, gastrointestinal, and other comorbidities. Using one drug to address multiple symptoms can reduce costs and improve medication compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.